Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy

Inclusion Criteria

• •1. Age ≥18 years at the time of study entry.
• •2. Patient with histologically documented metastatic and/or unresectable solid malignant tumor (NSCLC, head and neck, melanoma (except uveal melanoma), bladder cancer or any other advanced solid tumor when I-O agent is expected to be efficient or when a clinical trial is an option).
• •3. Patient for which a treatment with immune checkpoint blockade including, but not limited to, anti-PD-1, anti-PD-L1 and anti-CTLA-4 mAb alone or in combination has been decided.
• •4. Archived tumor specimen available or feasible for pre-treatment tumor biopsy.
• •5. Current treatment with ICB not yet started.
• •6. Evaluable disease (measurable as per RECIST 1.1. or not).
• •7. ECOG Performance status 0-2.
• •8. Patient able to participate and willing to give informed consent prior to performance of any study-related procedures.
• •9. Patient affiliated to a Social Health Insurance in France.